Switching From Reference Infliximab to Biosimilar CT-P13 Did Not Change Quality of Life in Stable Inflammatory Bowel Disease Patients.
Marieke J PierikAndrea E van der Meulen-de JongKlaas Van der LindeMaurice LutgensJohan Ph KuyvenhovenHalil AkolIds J KlompmakerMichelle S G SikkensYvonne J B van MegenCorinne M StoopJoanne P J Bloemsaat-MinekusGerard DijkstraPublished in: Crohn's & colitis 360 (2021)
Switching from reference infliximab to CT-P13 did not affect the QoL or disease activity and was well tolerated.
Keyphrases
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- end stage renal disease
- computed tomography
- image quality
- ejection fraction
- ulcerative colitis
- dual energy
- ankylosing spondylitis
- newly diagnosed
- chronic kidney disease
- contrast enhanced
- peritoneal dialysis
- prognostic factors
- juvenile idiopathic arthritis
- magnetic resonance imaging
- magnetic resonance
- patient reported outcomes